N/A N=32 Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women
Menopause · Hot Flashes · Vasomotor Disturbance
Primary: Tolerability of Gabapentin — 22; 4 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=137 Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
Giant Cell Glioblastoma · Glioblastoma · Gliosarcoma
Primary: Number of Patients Experiencing of Dose-limiting Toxicity (Cohort 1) — 0 participants
N/A N=12,024 The "START" (a Streamlined ART Initiation Strategy) Study
HIV
Primary: Cumulative Incidence of ART Initiation 14 Days After Clinical Eligibility in Treatment Eligible HIV-infected Patients — 2585; 3753 participants
Phase 2 N=49 Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Leukemia · Lymphoma
Primary: Overall Objective Response — 10; 5; 26; 4 Participants
Phase 1 N=96 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever
Dengue Fever
Primary: Number of Participants With Local Injection Site Reaction by Severity — 12; 1; 8; 2 participants
Phase 2 N=168 Adherence and Acceptability to and Blood Levels of Tenofovir Gel and Tablets in HIV Uninfected Women
HIV Infections
Primary: Self-reported Adherence to Each Regimen — 94; 93.8; 93.9 percentage of expected doses
N/A N=142 2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
Obsessive-Compulsive Disorder
Primary: Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) — -10.35; -9.40 Change in score from randomization
Phase 3 N=242 Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — -0.82; -0.39 score on a scale — p=<0.0001
Phase 4 N=87 Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy
Coronary Artery Disease
Primary: Lipiscan - Lipid Core Burden Index (LCBI) — 95.4; 132.4; 99.9; 99.8 ratio
Early Phase 1 N=10 Phase 0/1 Biomarker and Pharmacodynamic Study of Roflumilast in Patients With Advanced B-Cell Hematologic Malignancies (CTRC# 13-0013)
Advanced B-cell Lymphoid Malignancies
Primary: Total Number of Adverse Events. — 2 Adverse events
Phase 3 N=298 Primary Vaccination Study With GSK Biologicals' Pneumococcal Vaccine in Healthy Infants in Vietnam
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Grade 3 Symptoms (Solicited and Unsolicited) — 24; 3; 18; 3 Participants
N/A N=20 Duration of Infusion Set Function: Quick-Set Teflon Catheter Versus Sure-T Steel Infusion Set Catheter
Diabetes Mellitus
Primary: Length of Wear of Infusion Site — 137; 145 hours
Phase 3 N=294 Primary Vaccination With Either Synflorix™ or Prevenar 13™ or Both Vaccines and Booster Vaccination With Synflorix™
Infections, Streptococcal · Streptococcus Pneumoniae Vaccines
Primary: Number of Subjects With Grade 3 Adverse Events (AEs) (Solicited and Unsolicited) - Primary Period — 18; 10; 10; 12 Participants
N/A N=103 Laryngeal Mask Airway (LMA) for Surfactant Administration in Neonates
Respiratory Distress Syndrome
Primary: Need for Intubation and Mechanical Ventilation in the First Seven Days of Life. — 34; 19 Participants — p=0.006
Phase 4 N=150 Thoracoabdominal Arortic CTA Study
Thoracic Aortic Aneurysm
Primary: Radiation Dose — 35.1; 25.4; 25.5 mSv